Diffuse Cutaneous Systemic Sclerosis Dcssc clinical trials

Explore recruiting diffuse cutaneous systemic sclerosis dcssc clinical trials.

Recruiting diffuse cutaneous systemic sclerosis dcssc studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Diffuse Cutaneous Systemic Sclerosis Dcssc trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 2 Randomized, Double-blind, Placebo-Controlled Study to Assess the Safety and Efficacy of MTX-474 in the Treatment of Participants with Diffuse Cutaneous Systemic Sclerosis (dcSSc)

Netherlands, France

Therapeutic exploratory (Phase II) EU CTIS Study details

T-Guard against Autoreactive T cells in Systemic sclerosis: Erasion and Resolution (TASER)

Netherlands

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A randomized, double-blind, parallel group, placebo-controlled multicenter study to evaluate efficacy, safety and tolerability of ianalumab in participants with diffuse cutaneous systemic sclerosis

France, Greece, Portugal, Hungary, Italy, Germany +4 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase II, multi-part, five-year, randomized, open-label, assessor-blinded, active-controlled, multicenter study to evaluate the efficacy and safety of rapcabtagene autoleucel versus rituximab treatment in participants with severe refractory diffuse cutaneous systemic sclerosis

Italy, Spain, France, Netherlands, Germany, Austria +5 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A single-arm, open-label, multi-centre, phase I/II first-in-human study evaluating the safety and clinical activity of QEL-005, an autologous CAR T-regulatory cell therapy treatment targeting CD19, in patients with diffuse cutaneous systemic sclerosis (dcSSc) and in patients with difficult to treat rheumatoid arthritis (D2TRA).

Spain, Germany

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

The CALiPSO-1 Study: A Study of CNTY-101, a CD19-targeted CAR iNK Cell Product, in Participants with Refractory B cell-mediated Autoimmune Diseases

Italy, Germany, France

Human Pharmacology (Phase I)- Other EU CTIS Study details

Diffuse Cutaneous Systemic Sclerosis Dcssc trials by city

Diffuse Cutaneous Systemic Sclerosis Dcssc in Toronto Diffuse Cutaneous Systemic Sclerosis Dcssc in Vancouver Diffuse Cutaneous Systemic Sclerosis Dcssc in Montreal Diffuse Cutaneous Systemic Sclerosis Dcssc in Calgary Diffuse Cutaneous Systemic Sclerosis Dcssc in Edmonton Diffuse Cutaneous Systemic Sclerosis Dcssc in Ottawa Diffuse Cutaneous Systemic Sclerosis Dcssc in Winnipeg Diffuse Cutaneous Systemic Sclerosis Dcssc in Quebec City Diffuse Cutaneous Systemic Sclerosis Dcssc in Hamilton Diffuse Cutaneous Systemic Sclerosis Dcssc in Kitchener Diffuse Cutaneous Systemic Sclerosis Dcssc in London Diffuse Cutaneous Systemic Sclerosis Dcssc in Halifax Diffuse Cutaneous Systemic Sclerosis Dcssc in New York Diffuse Cutaneous Systemic Sclerosis Dcssc in Los Angeles Diffuse Cutaneous Systemic Sclerosis Dcssc in Chicago Diffuse Cutaneous Systemic Sclerosis Dcssc in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease